Stockscreener 앱 받기
23.42
0.30%
-0.07
시장 영업 전:
24.00
0.58
+2.48%
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Arcutis director Howard Welgus sells $164,219 in company stock - Investing.com
Arcutis director Howard Welgus sells $164,219 in company stock By Investing.com - Investing.com UK
Arcutis Biotherapeutics (ARQT) director sells 7,144 shares under 10b5-1 plan - Stock Titan
Director sale: Arcutis Biotherapeutics (NASDAQ: ARQT) plans to sell 684 shares - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) files to sell 1,341 vested shares via Merrill Lynch - Stock Titan
3,172-Share Form 144 Filed by Arcutis Biotherapeutics (NASDAQ: ARQT) - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) reports vesting and insider sales in Form 144 - Stock Titan
UBS Group AG Boosts Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Kornitzer Capital Management Inc. KS Takes Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Howard Welgus sells 30,000 ARQT shares (NASDAQ: ARQT) across three dates - Stock Titan
Will Arcutis Biotherapeutics, Inc. (ARQT) report negative earnings next week? What you should know - MSN
Jennison Associates LLC Has $196.25 Million Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Arcutis Biotherapeutics (ARQT) Expected to Announce Earnings on Wednesday - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Buys 147,586 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Calamos Advisors LLC Takes $1.57 Million Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis submits application to expand Zoryve use to infants - Investing.com UK
Arcutis Biotherapeutics (ARQT) Expands Zoryve Cream Application for Infants - GuruFocus
Arcutis submits sNDA for roflumilast cream 0.05% in atopic dermatitis for infants down to 3 months - Contemporary Pediatrics
Arcutis submits application to expand Zoryve use to infants By Investing.com - Investing.com South Africa
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months - The Manila Times
FDA filing targets eczema treatment for babies as young as 3 months - Stock Titan
ARQT Stock Price, Quote & Chart | ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) - ChartMill
Q4 2025 Arcutis Biotherapeutics Inc Earnings Call Transcript - GuruFocus
A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Moves - Yahoo Finance
How The Arcutis Biotherapeutics (ARQT) Narrative Is Shifting Around Zoryve And The $35 Target - Yahoo Finance
TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Arcutis Biotherapeutics (ARQT) and Valneva (VALN) - The Globe and Mail
ARQT (Arcutis Biotherapeutics Inc.) tops Q4 2025 EPS estimates on 91 percent year over year revenue growth, shares slip 2.03 percent.Crowd Risk Alerts - UBND thành phố Hải Phòng
Is Arcutis (ARQT) stock building trend strength (Investor Interest) 2026-04-22Crowd Sentiment Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines - The Manila Times
AAD backs steroid-free ZORYVE for children with eczema - Stock Titan
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
[ARS] Arcutis Biotherapeutics, Inc. SEC Filing - Stock Titan
Arcutis Biotherapeutics (ARQT) 2026 proxy details votes on board, pay and auditor - Stock Titan
Is Arcutis (ARQT) stock losing support (Slight Loss) 2026-04-20Collaborative Trading Signals - Cổng thông tin điện tử Tỉnh Sơn La
Arcutis Biotherapeutics (ARQT) Presents Positive Phase 2 Data for ZORYVE Cream in Infants - Insider Monkey
5 Overlooked Growth Stocks to Buy Now - Insider Monkey
Phocas Financial Corp. Trims Stake in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 - The Manila Times
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Arcutis to give business update with Q1 results after market close May 6 - Stock Titan
Arcutis Biotherapeutics (ARQT) price target increased by 10.24% to 35.70 - MSN
Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive - Yahoo Finance
Tudor Investment Corp ET AL Makes New Investment in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Emerges as a High-Growth Momentum Breakout Candidate - ChartMill
(ARQT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
AMI Asset Management Corp Sells 46,829 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Arcutis (ARQT) announces long-term phase 3 data for ZORYVE cream in children - MSN
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Is It Too Late To Revisit Arcutis Biotherapeutics (ARQT) After A 75% One-Year Surge? - Yahoo Finance
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know - The Globe and Mail
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know - The Motley Fool
0.14%
0.48%
자본화:
|
볼륨(24시간):